fashion -WSS

fashion

author：comprehensive 2025-10-02 08:24:20 - browse：7936

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Private equity could exacerbate cardiology's overuse problem, experts fear

WSS

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Diversifying clinical trials isn't enough to close racial gaps: study

Food makers tried to stack nutrition panel with preferred experts

New weight loss drugs vying to be the next Wegovy or Mounjaro

Physician subsidies by hospitals soar in wake of No Surprises Act

White House touts steps to stem shortages of cancer treatments

explore

fashion

hotspot

Peter Hotez and the public health issue of online harassment

Cassava reveals details — and problems — with Alzheimer's study

In Memoriam: Notable people who died in 2023

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

United colonoscopy coverage change 'may cost lives,' doctors say

Chimpanzees, like humans and whales, get menopause: Study

Malaria cases in Florida and Texas: Here’s what you need to know

Telehealth options flood the market as retailers push virtual care

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Wikipedia

Telehealth options flood the market as retailers push virtual care

Diversifying clinical trials isn't enough to close racial gaps: study

Food makers tried to stack nutrition panel with preferred experts

Will the IRA bring competition to the biologics market?

What to make of Biden’s latest efforts on cancer research

New Covid vaccine is recommended for everyone 6 months or older

leisure time

explore

explore

explore